- Patients must have measurable cutaneous KS disease, defined as: 1 or more marker lesion that is bi-dimensionally measureable, and ≥0.5cm in shortest dimension. These lesions must not have received previous local radiation, surgical, or intra-lesional cytotoxic therapy that would prevent response assessment.